GLP-1s demonstrate ‘large’ & ‘consistent’ protective effects against cancer metastases

CHICAGO — GLP-1 receptor agonists may help mitigate progression of at least some obesity-related cancers, according to retrospective study results presented at ASCO Annual Meeting.A database analysis of individuals diagnosed with stage I to stage III cancers showed those who used GLP-1 medications had lower risk for developing metastatic disease than those who used dipeptidyl peptidase-4